Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q8N138
UPID:
ORML3_HUMAN
Alternative names:
-
Alternative UPACC:
Q8N138; B3KS83; Q6UY83
Background:
ORM1-like protein 3 plays a pivotal role as a negative regulator of sphingolipid synthesis, which is crucial for cell membrane integrity and function. This protein's activity may indirectly influence endoplasmic reticulum-mediated calcium signaling, highlighting its importance in cellular homeostasis.
Therapeutic significance:
Given its association with asthma, a chronic disease marked by episodes of severe breathing difficulty, ORM1-like protein 3 represents a promising target for therapeutic intervention. Understanding its function and interaction with genetic and environmental factors could lead to novel treatments for asthma, improving quality of life for affected individuals.